LEGN Latest Headlines

Legend Biotech: Durable CARVYKTI Profile Supports Undervalued Buy Rating with Unchanged $65 Price Target

at www.tipranks.com (Thu, 29-Oct 9:15 AM)

Hold Rating Reiterated as Long-Term CAR-T Catalysts Offset Near-Term Uncertainty; $24 Price Target Maintained

at www.tipranks.com (Tue, 27-Oct 9:16 PM)

Legend Biotech (LEGN) Joins Gabelli’s Healthcare Symposium Panel on Oncology Innovation

Market Chameleon (Mon, 26-Oct 11:34 AM)

Legend Biotech Achieves Profitability and Breakthroughs in Cell Therapy with Q2 2026 Results

Market Chameleon (Tue, 11-Aug 7:35 AM)